Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Tightened Regulatory Grip Drops Daewoong and Dong-A Rx Sales In Q2, But OTC Sales Strong

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Affected by tightened government surveillance on inappropriate corporate activities, sales of prescription products of some Korean companies shrank in the second quarter while OTC products remained stable
Advertisement

Related Content

Dong-A Pharmaceutical, Meiji Seika Pharma Join For Biosimilar Distribution In Japan And Korea
Dong-A Pharmaceutical, Meiji Seika Pharma Join For Biosimilar Distribution In Japan And Korea
Green Cross Is Latest Korean Pharma To Struggle Under Regulatory Headwinds
Green Cross Is Latest Korean Pharma To Struggle Under Regulatory Headwinds
Korea To Suspend Licenses Of 390 Doctors, Pharmacists Over Rebates From Pharma Companies
Korea's Celltrion Sees Growth Trend Continue On Strength Of Biosimilar Validation Batch Orders
Korea Allows Sales Of OTC Products In Supermarkets July 21, But Distribution Remains A Challenge
Korean Government Launches Strongest-ever Drive To Root Out Rebates
Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing
Korean Analysts Retain Optimism For Daewoong Pharmaceutical On Early Pipeline and In-licensing
Advertisement
UsernamePublicRestriction

Register

SC078795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel